BSH 2023 | REFRACT: standard chemoimmunotherapy versus novel agents in R/R follicular lymphoma

  • Kim Linton

Press/Media: Research

Description

Video describing the REFRACT trial

Period24 Apr 2023

Media contributions

1

Media contributions

  • TitleBSH 2023 | REFRACT: standard chemoimmunotherapy versus novel agents in R/R follicular lymphoma
    Degree of recognitionInternational
    Media name/outletVJHaemOnc
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date24/04/23
    DescriptionKim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, shares some insights into the Phase II NCRI investigator-led REFRACT trial, which will evaluate novel therapies versus standard of care (SOC) chemoimmunotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Dr Linton highlights the various treatment arms being evaluated, and further explains that this trial will investigate potential novel biomarkers for early relapse and resistance to therapy. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
    Producer/AuthorVJHaemOnc
    URLhttps://www.vjhemonc.com/video/hkb0nydu2si-refract-standard-chemoimmunotherapy-versus-novel-agents-in-rr-follicular-lymphoma/
    PersonsKim Linton
View all 1
View less

Conference

Title63rd British Society of Haematology Annual Scientific Meeting
Location, Birmingham, United Kingdom
Period23 Apr 2023 → 25 Apr 2023

Related content